经肝动脉化疗栓塞术联合阿帕替尼治疗肝上皮样血管内皮瘤1例报告

张露; 王中峰; 宋立莎; 辛桂杰

doi:10.3969/j.issn.1001-5256.2019.06.033

经肝动脉化疗栓塞术联合阿帕替尼治疗肝上皮样血管内皮瘤1例报告

DOI: 10.3969/j.issn.1001-5256.2019.06.033

1. 吉林大学第一医院肿瘤中心
2. 吉林大学第一医院肝胆胰内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1298
- HTML全文浏览量: 12
- PDF下载量: 265
- 被引次数: 0
出版历程
- 出版日期: 2019-06-20

Transcatheter arterial chemoembolization combined with apatinib for the treatment of hepatic epithelioid hemangioendothelioma: A case report

Cancer Center, The First Hospital of Jilin University

摘要

摘要:
<正>1病例资料患者女性,39岁,因"肝占位"于2017年12月25日入本院。既往无病毒性肝炎、酒精性肝病及自身免疫性肝病等肝病史。患者体检发现肝占位,无腹痛、腹胀,无恶心、呕吐,无乏力、食欲下降及体质量下降。查体无黄染,肝脾未触及。辅助检查:ALT、AST、GGT、TBil、Alb水平均正常,血常规、尿常规、凝血常规、女性肿瘤标志物(CA724、CA242、CA125、CA199、CA153、CK19、CEA、AFP、神经元特异性烯醇化酶、鳞状细胞癌
- 肝肿瘤 /
- 血管内皮瘤 /
- 化学栓塞,治疗性 /
- 阿帕替尼 /
- 病例报告
- liver neoplasms /
- hemangioendothelioma /
- chemoembolization, therapeutic /
- apatinib /
- case reports

HTML全文

参考文献(12)

[1]MEHRABI A, KASHFI A, FONOUNI H, et al.Primary malignant hepatic epithelioid hemangioendothelioma:A comprehensive review of the literature with emphasis on the surgical therapy[J].Cancer, 2006, 107 (9) :2108-2121.

[2]YE F, JIANG LM, SONG Y, et al.Imaging features of hepatic epithelioid hemangioendothelioma[J].Chin J Dig Surg, 2017, 16 (2) :201-206. (in Chinese) 叶枫, 蒋力明, 宋颖, 等.肝脏上皮样血管内皮瘤的影像学特征[J].中华消化外科杂志, 2017, 16 (2) :201-206.

[3]ZHANG SH, CONG WM, WU MC, et al.Epithelioid hemangioendothelioma of the liver:A clinicopathological study on 8cases and review of literature[J].Chin J Hepatobiliary Surg, 2003, 9 (6) :327-330. (in Chinese) 张树辉, 丛文铭, 吴孟超.肝上皮样血管内皮瘤的临床病理特点 (附8例报告及文献复习) [J].中华肝胆外科杂志, 2003, 9 (6) :327-330.

[4]KAWAOKA T, AIKATA H, HYOGO H, et al, Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma[J].J Dig Dis, 2015, 16 (9) :505-512.

[5]EMAMAULLEE JA, EDGAR R, TOSO C, et al.Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma:Implications for treatment and surgical management[J].Liver Transpl, 2010, 16 (2) :191-197.

[6]SANGRO B, INARRAIRAEGUI M, FERNANDEZ-ROS N.Malignant epithelioid hemangioendothelioma of the liver successfully treated with sorafenib[J].Rare Tumors, 2012, 4 (2) :e34.

[7]SEMENISTY V, NARODITSKY I, KEIDAR Z, et al.Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option:Case report and review of anti-angiogenic treatment options[J].BMC Cancer, 2015, 15 (1) :1-5.

[8]KOLLAR A, JONES RL, STACCHIOTTI S, et al.Pazopanib in advanced vascular sarcomas:An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis[J].Acta Oncol, 2017, 56 (1) :88-92.

[9]NIZAMI I, MOHAMMED S, ABOUZIED MEL D.Pulmonary epitheloid hemangioendothelioma PET CT findings and review of literature[J].Ann Saudi Med, 2014, 34 (5) :447-449.

[10]CHEVREAU C, le CESNE A, ITALIANO A, et al.Sorafenib in patients with progressive epithelioid hemangioendothelioma:Aphase 2 study by the French Sarcoma Group (GSF/GETO) [J].Cancer, 2013, 119 (14) :2639-2644.

[11]LI J, QIN S, XU J, et al.Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].J Clin Oncol, 2016, 34 (13) :1448-1454.

[12]ZHENG Z, WANG H, JIANG H, et al.Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma:A case report and literature review[J].Medicine, 2017, 96 (45) :e8507.

施引文献

资源附件(0)

访问统计